<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830895</url>
  </required_header>
  <id_info>
    <org_study_id>SNUH-RENAL-0901</org_study_id>
    <nct_id>NCT00830895</nct_id>
  </id_info>
  <brief_title>RAD001 for Non-clear Cell Renal Cell Carcinoma (RCC)</brief_title>
  <official_title>A Phase II Study to Evaluate the Efficacy of RAD001 in Metastatic Non-clear Cell Renal Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the efficacy and safety of RAD001 (everolimus) in non-clear cell renal cell
      carcinoma
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>2 months, 4 months, 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>2 months, 4 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-control rate</measure>
    <time_frame>2 months, 4 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 months, 4 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic response rate by FDG-PET</measure>
    <time_frame>2 months, 4 months, 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>monthly</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>RAD001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>RAD001 10mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RAD001</intervention_name>
    <description>RAD001 10mg/day</description>
    <arm_group_label>RAD001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically or cytologically confirmed non-clear cell renal cell carcinoma
             (papillary, chromophobe, collecting duct, oncocytic subtype, sarcomatoid mainly)

          2. Subjects with metastatic legion

          3. Subjects aged 18 years or older

          4. Subjects whose ECOG performance status is 0 or 1

          5. Subjects who have laboratory value below; Hematology

               -  Neutrophil &gt;= 1.5 x 109/L

               -  Platelet &gt;= 75 x 109/L

               -  Hemoglobin &gt;= 9 g/dL Liver function tests

               -  Total bilirubin ≤ 1.5 xULN

               -  AST, ALT ≤ 2.5 xULN

               -  Alkaline phosphatase ≤ 2.5 xULN Renal function tests

               -  Creatinine clearance &gt;= 30 mL/min

          6. Subjects who understand and provide a written informed consent

        Exclusion Criteria:

          1. Subjects who have been administered an mTOR inhibitor

          2. Pregnant or nursing women, and women of childbearing potential must use appropriate
             contraception for the study period and the result of their pregnancy test performed
             within 14 days before enrollment must be negative

          3. Subjects who participated in a clinical study using the study medication within 30
             days before randomization

          4. Subjects with clinically uncontrolled central nervous system (CNS) metastasis

          5. Subjects with life expectancy of less than 3 months

          6. Subjects with interstitial pulmonary disease

          7. Subjects whose QTc interval is prolonged (QTc &gt; 450 msec for male or &gt; 470 msec for
             female)

          8. Other serious diseases or medical conditions Heart disease unstable despite treatment
             History of myocardial infarction within six months before the study History of serious
             neurological or psychological disorder including dementia or seizure Active peptic
             ulcer which cannot be controlled by a drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 27, 2009</study_first_submitted>
  <study_first_submitted_qc>January 27, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2009</study_first_posted>
  <last_update_submitted>April 11, 2013</last_update_submitted>
  <last_update_submitted_qc>April 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Se-Hoon Lee</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Renal cell carcinoma</keyword>
  <keyword>Non-clear cell</keyword>
  <keyword>RAD001</keyword>
  <keyword>Metastatic, non-clear cell, renal cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

